Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Share-based Compensation (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Share-based Compensation for 6 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 84.45% to $2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.5 million, a 7.27% decrease, with the full-year FY2025 number at $12.5 million, down 7.27% from a year prior.
  • Share-based Compensation was $2.8 million for Q4 2025 at Lexicon Pharmaceuticals, down from $3.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.9 million in Q2 2024 to a low of $1.5 million in Q4 2024.
  • A 3-year average of $3.4 million and a median of $3.3 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: crashed 52.15% in 2024, then surged 84.45% in 2025.
  • Lexicon Pharmaceuticals' Share-based Compensation stood at $3.2 million in 2023, then plummeted by 52.15% to $1.5 million in 2024, then soared by 84.45% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Share-based Compensation are $2.8 million (Q4 2025), $3.4 million (Q3 2025), and $3.2 million (Q2 2025).